Home » Stocks » QLGN » Company

Qualigen Therapeutics, Inc. (QLGN)

Stock Price: $1.95 USD -0.01 (-0.51%)
Updated Jun 22, 2021 4:00 PM EDT - Market closed
After-hours: $1.98 +0.03 (1.54%) Jun 22, 7:22 PM
Qualigen Therapeutics, Inc.
Country United States
Founded 1996
Industry Biotechnology
Sector Healthcare
Employees 34
CEO Andrew Ritter

Contact Details

Address:1880 Century Park E Ste 1000
Los Angeles, California 90067
United States
Phone 760 918 9165

Stock Information

Ticker Symbol QLGN
Exchange NASDAQ
Fiscal Year April - March
Reporting Currency US Dollars
CIK Code 1460702
ISIN Number US74754R1032

Company Description

Qualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases.

It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood.

Qualigen, Inc. was founded in 1996 and is based in Carlsbad, California.

Key Executives

Michael S. PoirierChairman, Chief Executive Officer and Pres
Christopher L. LotzVice President of Finance and Chief Financial Officer
Shishir K. SinhaVice President of Operations and Corporate Secretary
Dr. Wajdi Abdul-AhadVice President of Research & Development and Chief Scientific Officer
Amy S. BroidrickExecutive Vice President, Chief Strategy Officer and Director
Tariq Arshad M.B.A., M.D.Senior Vice President and Chief Medical Officer